Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 7/20 | 0.66 |
| ▸ | GRM5 | P41594 | 3/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CD38 | P28907 | 3/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9893679 | 0.92 | MDM2 (0.79) | MDM2GRM5NOTUM | |
| SCHEMBL1438330 | 0.91 | MDM2 (0.67) | MDM2GRM5NOTUMMAPTCD38 | |
| SCHEMBL9893678 | 0.89 | MDM2 (0.62) | MDM2GRM5JAK2TGFBR1 | |
| SCHEMBL1436891 | 0.87 | MDM2 (0.85) | MDM2IKBKBNOTUMMAPTPTPN11 | |
| SCHEMBL27862905 | 0.85 | MDM2 (0.53) | MDM2GRM5NOTUMJAK2CD38 | |
| SCHEMBL1436927 | 0.85 | MDM2 (0.75) | MDM2IKBKBNOTUMMAPTPTPN11 | |
| SCHEMBL1437096 | 0.83 | MDM2 (0.79) | MDM2GRM5NOTUM | |
| SCHEMBL9893983 | 0.83 | MDM2 (0.46) | MDM2MAPT | |
| SCHEMBL9894082 | 0.81 | MDM2 (0.51) | MDM2GRM5NOTUMTGFBR1 | |
| SCHEMBL9894128 | 0.80 | MDM2 (0.85) | MDM2NOTUMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | MDM2 2/4885GRM5 3019/4885IKBKB 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.